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Background: The baseline levels of serum procalcitonin (PCT) have not been determined in patients with end-stage
renal disease needing renal replacement therapy. The purpose of the present study is to verify the reference range of
PCT and parameters affecting its value in patients receiving chronic hemodialysis.
Methods: A total of 125 dialytic patients who had no obvious clinical signs of systemic infection were included in this
prospective observational study. The PCT level was measured, and its relationships to other clinical and laboratory
parameters were evaluated.
Results: The baseline PCT levels of 82 male and 43 female patients were evaluated. Mean baseline PCT level was
0.24 ± 0.22 ng/ml. Sixteen (12.8 %) patients showed elevated PCT (>0.3 ng/ml) and C-reactive protein (CRP) (>0.3 mg/dl),
and 11 (8.8 %) patients showed only abnormal PCT. In 9 patients (7.2 %), PCT levels exceeded 0.5 ng/ml, which is a
common cutoff point for sepsis although they had no clinical signs of systemic bacterial infection. The PCT level was
statistically correlated with the duration of chronic dialysis, urine volume per day, dialysis time, the serum CRP,
β2-microglobulin levels, and normalized dialysis dose.
Conclusions: Most dialysis patients had PCT levels within the reference range of non-dialytic individuals. However, a not
negligible number of patients had higher PCT levels than the upper limit of healthy individuals, despite there being no
sign of infection. Impairment of renal function and hemodialytic status may affect PCT level.
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Serum procalcitonin (PCT) is a 116-amino acid peptide
with a low molecular weight of about 13 kDa. The serum
PCT level in healthy individuals is under 0.3 ng/ml. In the
life-threatening septic condition due to severe bacterial in-
fection, the serum PCT level exceeds 0.5 ng/ml [1]. On the
other hand, the baseline levels of serum PCT have not
been determined in patients with chronic kidney disease
(CKD), including end-stage renal disease (ESRD) needing
renal replacement therapy. Although Herget-Rosenthal
et al. [2] utilized the cutoff point of 1.5 ng/ml for detection
of sepsis in hemodialytic patients in their report, their* Correspondence: kichi@sapmed.ac.jp
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sepsis but only a small number of those with no sign of
infection. To utilize PCT as a serum marker in ESRD
patients for detection or exclusion of sepsis, it is necessary
to clarify the baseline level of serum PCT in these patients.
In this study, we measured levels of serum PCT in pa-
tients with hemodialysis (HD) and hemodiafiltration
(HDF) who had no obvious clinical signs of severe systemic
bacterial infection to verify the baseline level. In addition,
parameters affecting the baseline PCT level in these pa-
tients were also evaluated.Methods
Patient inclusion criteria and study design
This non-randomized, non-controlled prospective obser-
vational study enrolled 125 adult patients with ESRDe is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Patient characteristics
Mean ± SD (range) Number (%)
Age (years) 66 ± 11 (34–89)
Male/female 82 (65.6)/43 (34.4)
Duration of dialysis (years) 6 ± 5 (0–23)
Urine volume/day (ml) 231 ± 295 (0–1000) 64 (51.2)
Primary disease
DM nephropathy 57 (45.6)
Non-DM 68 (54.4)
CGN 19 (15.2)





HD/HDF 112 (89.6)/13 (10.4)
Blood access
Native AVF/AVG 114 (91.2)/11 (8.8)
Dialysis time (hours) 3.9 ± 0.5 (2.3–5.2)
Fluctuation of BP during
dialysis
Systolic pressure 44 ± 23 (−38–134)
Diastolic pressure 20 ± 12 (−24–59)
Serum creatinine (mg/dl) 9.5 ± 2.3 (2–15.1)
White blood cell counts
(×103/μL)
5.55 ± 2.16 (2.32–16.9)
C-reactive protein (mg/dl) 0.3 ± 0.8 (0–7.4)
Ferritin (ng/ml) 133 ± 108 (5–796)
β2 microglobulin (mg/dl) 25.7 ± 6.2 (8.7–42.7)
Intact PTH (pg/ml) 149 ± 93 (5–496)
albumin (g/dl) 3.3 ± 0.3 (2.2–4.0)
Kt/V equivalent 1.23 ± 0.26 (0.41–1.74)
nPCR (g/kg/day) 0.82 ± 0.17 (0.35–1.45)
Total body water (ml/kg) 557 ± 48.6 (428–722)
CGN chronic glomerular nephritis, DM diabetes mellitus, HD hemodialysis, HDF
hemodiafiltration, AVF arteriovenous fistula, AVG arteriovenous graft, BP blood
pressure, nPCR normalized protein catabolic rate
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tients received dialysis by using a high-flux membrane.
Overall, 11 patients had arteriovenous graft for dialysis.
There was no patient who had a trouble in the blood ac-
cess at the time of PCT measurement. All patients were
clinically stable, were free from clinical signs of systemic
infection, and had no history of surgery during 1 month
prior to this study. They had been receiving clinical and
laboratorial evaluation routinely to detect the sign of
infection every 2 weeks since dialysis induction. Systemic
computed tomography was done to rule out active infec-
tious disease if patients had physical and laboratory find-
ings suggestive of infection such as high fever exceeding
38 °C, C-reactive protein (CRP) elevation, or leukocytosis.
We obtained plasma and serum samples from them
before dialysis when 2 days had passed from the last dia-
lysis because the timing was reliable to evaluate static
state in hemodialytic patients. PCT levels were measured
by electrochemiluminescence immunoassay. The results
were compared to the normal cutoff level (0.3 ng/ml)
and that of sepsis (0.5 ng/ml) in normal individuals. In
addition, we calculated the variables associated with dialytic
efficiency and the nutrition index by using data obtained
from blood samples before and after dialysis. The correla-
tions between PCTand these variables were evaluated.
The study protocol was approved by the institutional
review board and conducted in accordance with the eth-
ical principles that have their origin in the Declaration
of Helsinki (acceptance number 24-93). All participants
provided signed informed consent before joining the
study.
Statistical analysis
PCT data was presented as mean (±standard deviation)
and median (range) value. The differences in PCT data
between groups were examined using Mann-Whitney
U test as non-parametric analysis. Correlations were
determined by Spearman’s rank correlation test as uni-
variate analysis. Correlation coefficient more than ±0.8
was defined as strong association in this study. More-
over, multiple linear regression analysis was performed
to detect independent parameter that could predict
PCT elevation using the variables which showed sig-
nificant correlation in univariate analysis. However, if
each parameter had strong or opposite correlation, the
variables which had stronger correlation with PCT
were selected to exclude multicollinearity. All statis-
tical tests were two-sided, and statistical significance
was defined as a p value of less than 0.05.
Results
Patients’ characteristics and baseline serum PCT levels
The characteristics of 125 patients are shown in Table 1,
and the distribution of serum PCT concentration is shownin Fig. 1a. The mean and median baseline serum PCT
levels of them were 0.24 ± 0.22 and 0.18 ng/ml (0.05–1.73),
respectively. Of them, the PCT levels in 27 patients
(21.6 %) were elevated to above 0.3 ng/ml, which is the
upper limit of the normal range in healthy individuals.
Moreover, 9 patients (7.2 %) had baseline serum PCT levels
of over 0.5 ng/ml, which is the cutoff point suggestive of
sepsis in non-dialytic individuals. The details of them were
shown in Table 2.
In this cohort, 20 (16 %) patients had leukocytosis
(>104/μl) and/or elevated CRP (>0.3 mg/dl) in spite of
normal PCT (≤0.3 ng/ml). Furthermore, 16 (12.8 %)
Fig. 1 Distribution of serum procalcitonin level in patients receiving chronic hemodialysis with no evidence of bacterial infection. a Distribution
in all 125 patients included in this study. b Distribution in 89 patients with normal C-reactive protein and white blood cell counts. The median is
indicated by the horizontal line within the box, and the box shows the interquartile range (IQR). The upper whisker indicates the 75th percentile +
1.5 × IQR. The lower whiskers indicate the 25th percentile − 1.5 × IQR and upper w. Circles represent outliers extending more than 1.5 box lengths
from the box edge
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tients had potentially localized or latent infectious disease,
although other clinical examinations and clinical courses
did not suggest such status. Therefore, the distribution of
PCT levels in the remaining 89 patients after excluding
those with leukocytosis and/or elevated CRP is shown in
Fig. 1b. The mean and median baseline serum PCT levels
of them were 0.23 ± 0.25 and 0.17 ng/ml (0.05–1.73),
respectively. Also among these patients, 5.6 % had baseline
serum PCT levels of over 0.5 ng/ml.
All the nine patients with PCT over 0.5 ng/ml received
further evaluations, including physical examination, ab-
dominal computed tomography, chest X-ray, and/or blood
culture, to detect the focus of bacterial infection. However,Table 2 Details of the patients with procalcitonin exceeded 0.5 ng/
No. Age Sex PCT (ng/ml) CRP (mg/dl) WBCs (×103/μl) Mo
1 59 Female 0.51 3.7 6.25
2 65 Male 0.53 0 6.9
3 73 Male 0.54 0.6 7.96
4 84 Male 0.6 1.6 7.62
5 62 Male 0.65 0.1 6.1
6 85 Male 0.84 0.2 3.53
7 77 Male 0.95 0.6 3.5
8 56 Female 1.52 0.2 6.71
9 58 Female 1.73 0 3.22
PCT procalcitonin, CRP C-reactive protein, WBCs white blood cell counts, HD hemodobvious infectious disease could not be detected. Recon-
firmation of PCT was performed at more than 12 months
after the initial examination in only four cases (Nos
(Numbers) 2, 3, 5, and 6 in this cohort, whose PCT levels
were 0.47, 0.44, 0.20, and 0.61 ng/ml, respectively),
whereas the remaining patients were lost to follow-up or
died of cerebrovascular disease.
The variables correlated with PCT
The relationships between variables and PCT are exam-
ined by Mann-Whitney U test and Spearman’s rank
correlation test in 125 patients and shown in Table 3.
The duration of dialysis (R = 0.245, p = 0.0073), dialysis time
(R = 0.281, p = 0.0033), CRP (R = 0.278, p = 0.0022), serumml










ialysis, HDF hemodiafiltration, AVF arteriovenous fistula, AVG arteriovenous graft
Table 3 Results of the correlations between procalcitonin (PCT)
and the other variables using Mann-Whitney U test and Spearman’s
rank correlation test in 125 patients




Male (82) 0.238, 0.185 (0.05–0.95)
Female (43) 0.264, 0.170 (0.05–1.73)
Primary disease 0.4330
DM nephropathy (57) 0.222, 0.180 (0.05–0.84)
Non-DM (68) 0.268, 0.185 (0.05–1.73)
Modality of hemodialysis 0.0831
HD (112) 0.240, 0.180 (0.05–1.73)
HDF (13) 0.308, 0.240 (0.11–0.95)
Blood access 0.8205
Native AVF (114) 0.242, 0.180 (0.05–1.73)
AVG (11) 0.304, 0.190 (0.10–1.52)
Age 0.071 0.4408
Duration of dialysis 0.245 0.0073
Urine volume/day (64) −0.348 0.0057
Dialysis time 0.281 0.0033
Fluctuation of BP during
dialysis
Systolic pressure 0.048 0.5939
Diastolic pressure 0.102 0.2556
Serum creatinine 0.136 0.1342
White blood cell counts 0.159 0.0784
C-reactive protein 0.278 0.0022
Ferritin 0.096 0.2933
β2 microglobulin 0.229 0.0112
Intact PTH 0.048 0.6061
Albumin −0.125 0.1350
Kt/V equivalent 0.352 <0.0001
nPCR 0.125 0.1685
Total body water volume −0.007 0.9264
Pts patients, DM diabetes mellitus, HD hemodialysis, HDF hemodiafiltration,
AVF arteriovenous fistula, AVG arteriovenous graft, Kt/V normalized dialysis
dose, BP blood pressure, nPCR normalized protein catabolic rate
Table 4 Results of correlations between procalcitonin (PCT) and
the other variables in 89 patients without leukocytosis and
elevated CRP




Male (59) 0.210, 0.170 (0.05–0.84)
Female (30) 0.267, 0.165 (0.05–1.73)
Primary disease 0.5464
DM nephropathy (40) 0.203, 0.165 (0.05–0.84)
Non-DM (49) 0.250, 0.170 (0.05–1.73)
Modality of hemodialysis 0.7601
HD (82) 0.232, 0.170 (0.05–1.73)
HDF (7) 0.191, 0.170 (0.11–0.31)
Blood access 0.5319
Native AVF (81) 0.218, 0.170 (0.05–1.73)
AVG (8) 0.341, 0.195 (0.10–1.52)
Age −0.038 0.7012
Duration of dialysis 0.301 0.0054
Urine volume/day (45) −0.247 0.0703
Dialysis time 0.406 0.0002
Fluctuation of BP during
dialysis
Systolic pressure 0.114 0.2929
Diastolic pressure 0.163 0.1315
Serum creatinine 0.293 0.0062
White blood cell counts 0.068 0.5308
C-reactive protein 0.113 0.3371
Ferritin 0.074 0.4956
β2 microglobulin 0.193 0.0728
Intact PTH 0.080 0.4645
Albumin 0.015 0.9532
Kt/V equivalent 0.398 0.0002
nPCR 0.109 0.3128
Total body water volume −0.127 0.2263
Pts patients, DM diabetes mellitus, HD hemodialysis, HDF hemodiafiltration,
AVF arteriovenous fistula, AVG arteriovenous graft, Kt/V normalized dialysis
dose, BP blood pressure, nPCR normalized protein catabolic rate
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and normalized dialysis dose (Kt/V) equivalent (Kt/Ve)
(R = 0.352, p < 0.0001) had statistically significant posi-
tive correlations with PCT although the importance of
association in each variable was weak. In addition, urine
volume per day (R = −0.348, p = 0.0057) had a signifi-
cant negative correlation with PCT. On the other hand,
primary disease, the type of vascular access, and modality
of hemodialysis were not correlated with PCT. Multiple
linear regression analysis was performed using parameterswhich had significant correlation in univariate analysis ex-
cept for dialysis time. Finally, no statistically significant
parameter which could predict PCT elevation was deter-
mined in this cohort.
As subanalysis, we also evaluated the correlation in 89
patients with normal CRP and without leukocytosis
(Table 4). The duration of dialysis (R = 0.301, p = 0.0054),
dialysis time (R = 0.406, p = 0.0002), serum creatinine
(R = 0.293, p = 0.0062), and Kt/Ve (R = 0.398, p = 0.0002)
showed statistically significant correlation, but no variable
could predict PCT elevation.
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PCT is accepted widely in real life clinical practice as a
marker not only for diagnosis but also for the thera-
peutic effectiveness of treatment for sepsis due to bacter-
ial infection. However, the static and dynamic statuses of
PCT in patients with ESRD have remained unclear, par-
ticularly for those receiving HD or HDF. A limited num-
ber of reports showed that PCT was a useful diagnostic
marker for systemic bacterial infections in patients with
renal insufficiency [3, 4]. It is well known that impaired
renal function and the non-physiologic status related to
chronic hemodialysis can affect some biochemical and
hormonal measurements. To date, an appropriate cutoff
point for serum PCT suggesting systemic bacterial infec-
tion in ESRD patients has not been determined. There-
fore, we think that it is important to investigate the
baseline levels of serum PCT in ESRD patients with no
evidence of bacterial infection to utilize PCT for ESRD pa-
tients in clinical settings. To the best of our knowledge,
this study included the largest number of those with ESRD
with no evidence of systemic bacterial infection.
In the present study, PCT levels in most ESRD pa-
tients receiving chronic hemodialysis were the same as
those in healthy individuals. However, 27 of the 125 pa-
tients (21.6 %) had PCT levels exceeding 0.3 ng/ml, in-
cluding 9 with PCT >0.5 ng/ml. Two of these 9 patients
(nos. 8 and 9) had extremely high PCT levels, despite
stable general condition and no abnormal findings in
any other examinations. Although ESRD patients with
dialysis sometimes lack subjective symptoms, they nor-
mally exhibit some objective findings such as high fever,
tachycardia, tachypnea, and/or hypotension when suffer-
ing from severe infection or sepsis. Therefore, the soli-
tary elevation of PCT is unlikely to mean early detection
of infectious disease. Although repeated measurement
was done only in 4 patients, 3 of them had the same
level as the initial level.
The PCT level can be elevated in patients with renal in-
sufficiency since PCT is a low molecular weight protein
that can be filtered by the renal glomerulus and absorbed
by the renal tubules [5]. Herget-Rosenthal et al. [6]
reported that the PCT level gradually increased according
to the degree of deterioration in renal function and was
influenced by the type of the renal replacement therapy.
The baseline levels of PCT in CKD patients at stages I to
IV did not differ from those in controls. On the other
hand, PCT levels in patients with stage V CKD and peri-
toneal dialysis (PD) were significantly higher than those in
controls and patients with stages I to IV CKD. PCT levels
in hemodialytic patients were significantly higher than
those in CKD and PD patients in any stage. In general, PD
patients tend to have more residual renal function than
hemodialytic patients, which may be the reason for the
difference of PCT levels between them.In our study, PCT had positive correlations to the dur-
ation of dialysis, dialysis time, β2MG, and Kt/Ve and a
negative correlation to urine volume. A longer period of
hemodialysis, longer dialysis in each session, and higher
Kt/Ve and decreased urine volume were all associated
with dependence on hemodialysis and might be corre-
lated to lesser residual renal function. β2MG is low
molecular weight protein like PCT and increases in rela-
tion to the duration of dialysis. These results supported
the relationship between the residual renal function and
PCT level. Furthermore, PCT in HDF patients tended to
be higher than that in patients with HD, although there
was no statistically significant difference. HDF is thought
to be appropriate for patients with longer duration of
receiving hemodialysis because such patients often have
hemodynamic trouble during dialysis or have high β2MG.
Residual renal function tends to be low in these patients,
which may explain the higher PCT level in HDF patients.
However, the number of HDF patients in the present
study was too small, and further study is needed to clarify
this situation.
On the other hand, it may be difficult to explain the in-
crease in PCT levels only by the decrease in residual renal
function because the amount of PCT produced in thyroidal
C cells is usually extremely small in healthy individuals.
Uremia has various influences on the general condition of
patients with ESRD [7]. Inflammatory cytokines produced
and released by uremia cause chronic inflammation in the
whole body. The activation of TNF-alpha, an inflammatory
cytokine, is well known to promote PCT production [1]. In
addition, uremia promotes the release of acute phase
inflammatory reaction substances like CRP. Uremia may
potentially induce the production of PCT in hemodialytic
patients. In this study, patients with high PCT levels did
not always have elevated CRP or leukocytosis. However,
there was a correlation between PCT and CRP, production
of both of which might be due to inflammatory cytokines
induced by uremia. Thus, uremia might also be an explan-
ation for the increase in baseline PCT levels in patients
with dialysis, although we did not evaluate the serum levels
of inflammatory cytokines in this study. On the other hand,
we could not show a statistically significant correlation
between WBC and PCT. The function of WBCs can de-
teriorate due to uremia, malnutrition, and various drugs.
Moreover, the number of WBCs in the peripheral blood is
changed by dialysis [8]. These factors might affect the dis-
crepancy between the elevation of PCT and WBCs.
The type of dialysis membrane can affect the PCT levels
[2, 9]. Hemodialysis with a high-flux membrane removes
30–80 % of PCT in the serum, and the influence lasts for
more than 48 h although a low-flux membrane does not
dialyze PCT. Because the current study did not include pa-
tients receiving hemodialysis with a low-flux membrane,
the influence of the type of membrane could not be
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tients before dialysis when 2 days had passed from the last
dialysis. Thus, there might be little influence of the dialysis
membrane in this study. Further study is needed to clarify
the effect of the membrane on the baseline PCT level.
According to the results of a meta-analysis of ESRD pa-
tients, the upper limit of the reference range of PCT
should be set higher than that in normal individuals [10].
Herget-Rosenthal et al. [2] suggested that 1.5 ng/ml was
an appropriate cutoff point for serum PCT to detect se-
vere infection or sepsis in hemodialytic patients. In the
present study, the baseline PCT levels in dialytic patients
were almost same as those of healthy individuals. How-
ever, 21.6 % of 125 patients and even 12.4 % of 89 patients
with normal CRP and white blood cell counts showed
PCT more than 0.3 ng/ml. Therefore, actual cutoff value
of the baseline PCT in hemodialytic patients might be
higher than that in healthy individuals.
Recently, the efficacy of PCT-guided antibiotic therapy
for patients with severe sepsis has been investigated [11].
The study recommended that the PCT levels to initiate
and discontinue antibiotic therapy be determined differ-
ently according to the individual conditions. For utilization
of PCT as a guide for antibiotic chemotherapy in HD pa-
tients, it is essential to determine the normal range of PCT
in the patients. Because the present study provided only
preliminary data, further study to determine the normal
range is needed.
A major limitation of this study is that we could not
absolutely determine that the patients were free of infec-
tion including localized infection. PCT is known as a
useful marker for systemic bacterial infection or sepsis.
At least, systemic bacterial infection and sepsis could be
rule out in this series because all of them were healthy
and did not have clinical signs such as fever or poor gen-
eral condition. Therefore, we thought that the results of
our study was extremely important finding although fur-
ther investigations are needed to clarify that serum PCT
can be elevated in dialytic patients with localized infec-
tion. In addition, the number of patients in this study
was relatively small, and larger studies are needed to de-
termine the reference range in dialytic patients.
Conclusions
Most of the patients with hemodialysis showed normal
PCT. However, a not negligible number of them had
higher baseline PCT level than those in healthy individuals.
In 7.2 % of them, serum PCT exceeded the cutoff point for
sepsis in healthy individuals. Impairment of renal function
and hemodialytic status may affect the PCT level.
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